Inflammation, fibrosis, infection, or vascular injury reduces functional nephrons.
The kidney is the primary site of Klotho synthesis. Fewer nephrons means less circulating Klotho.
Without Klotho, TGF-β-driven fibrosis accelerates, tubular oxidative stress rises, phosphate dysregulation worsens.
Accelerated fibrosis and inflammation compound the original damage, the cycle tightens.
Klotho levels decline by over 80% across the adult lifespan — from ~1,500 pg/mL in the twenties to 120–250 pg/mL after age 50. In CKD, this decline is further accelerated by the destruction of the very tissue responsible for producing it. This is why Klotho restoration is not a peripheral intervention in kidney disease — it addresses a central, self-perpetuating mechanism of its progression.
Drop in circulating Klotho across the adult lifespan.
Klotho directly inhibits TGF-β-mediated pro-fibrotic signalling in tubular cells — the primary driver of scar tissue formation in CKD. Restoring Klotho interrupts the fibrotic remodelling that progressively replaces functional nephrons with connective tissue.
Tubular cells are among the most metabolically demanding in the body. Klotho reduces oxidative and endoplasmic reticulum stress in these cells, protecting against the apoptotic cell death that drives nephron loss in chronic disease.
As co-receptor for FGF23, Klotho governs phosphate reabsorption in the proximal tubule. Dysregulated phosphate — a hallmark of CKD — drives vascular calcification, soft tissue mineralisation, and accelerated cardiovascular disease in renal patients.
Klotho suppresses NF-κB activation and reduces TNF-α and IL-6 production within glomerular and tubulointerstitial compartments — reducing the inflammatory burden that sustains both renal and systemic damage.
Five patients · Minicircle Klotho gene therapy · Blast Longevity, Los Cabos · Report: B. Hanly PhD, March 2026. eGFR improved in 5 of 5 patients with available serial data. Creatinine declined in 4 of 4 measured patients. Improvements sustained at 12-month follow-up in two patients with adequate longitudinal data — suggesting lasting structural change, not transient hormonal effect.
All patients with serial data
All measured patients
Patient M, 81 years, 3 months
Patients with full follow-up
Female · 54 · Acute kidney injury (UTI)
5.34 →1.87
1852 →419
6% → 24%
eGFR recovered from a nadir of 9 to 32 within approximately three weeks of Klotho administration. Creatinine fell from 5.34 to 1.87 mg/dL over the same period. Attending emergency physicians noted the speed of recovery was inconsistent with the expected trajectory given the severity of the acute-on-chronic injury.
Largest absolute eGFR gain in cohort.
Largest absolute eGFR gain in the cohort, in the oldest patient, where age-related nephron loss typically makes such gains unlikely without active intervention.
Sustained at 7-month follow-up.
Consistent improvement sustained at 7-month follow-up despite a transient dip at time of injection.
15-month observation window.
Improvement sustained at 10-month follow-up. N/L ratio improved markedly within 2 months, reduced systemic inflammatory tone.
5-month follow-up.
Consistent directional improvement at 5-month follow-up across all measured parameters.
Klotho directly inhibits TGF-β-mediated pro-fibrotic signalling in tubular cells — the primary driver of scar tissue formation in CKD. Restoring Klotho interrupts the fibrotic remodelling that progressively replaces functional nephrons with connective tissue.
If Klotho-mediated renal protection induces durable structural change while immune modulation requires ongoing signalling, structural gains may need only bi-annual reinforcement, while immune and cognitive benefits may benefit from earlier re-dosing. Longitudinal data collection is ongoing.
Klotho’s renal protection extends directly into cardiovascular protection — because the two systems share the same Klotho-dependent signalling pathways. Phosphate dysregulation in CKD is a primary driver of vascular calcification and arterial stiffness. Endothelial dysfunction follows. The heart fails partly because the kidneys failed first.
Klotho prevents vascular calcification by regulating phosphate and FGF23 signalling — one of the most direct links between CKD progression and cardiovascular mortality.
Klotho improves nitric oxide bioavailability and reduces endothelial inflammation — restoring vasodilation capacity and reducing arterial stiffness independently of blood pressure control.
The neutrophil-to-lymphocyte ratio improved consistently across the cohort within 2 months of therapy — a systemic marker of reduced inflammatory tone with direct cardiovascular relevance.
Across four of the five patients, the neutrophil-to-lymphocyte ratio improved within two months of Klotho therapy — consistent with a shift toward a less inflammatory immune profile. In Patient D, this shift persisted at 10-month follow-up. In Patient M (81 years), the N/L ratio moved from 70/19 to 64/24 within three months — alongside the largest eGFR gain in the cohort. The co-occurrence of renal recovery and immune rebalancing is mechanistically coherent: Klotho suppresses the same NF-κB and cytokine pathways that drive both renal and vascular inflammation.
Non-viral, non-integrating. No bacterial backbone — minimal immune activation. No genomic insertion risk.
Adipocytes act as sustained secretory depots — producing and releasing circulating Klotho continuously after transfection.
Plasma Klotho rises within one week of administration and remains elevated for 8–14 months from a single injection.
By restoring what kidney disease takes away, Klotho minicircle therapy addresses a central degenerative mechanism — not just a downstream marker. Our clinical data show that even in severely compromised kidneys, this restoration produces measurable, structural improvement. The data are preliminary. The signal is consistent.
The Art of Illusion Restoration Ideal for:
Creating the look of a fuller head of hair, adding density to thinning areas, or complementing a hair transplant by adding depth.
The Science:
This is a non-invasive cosmetic tattooing technique where we deposit micro-dots of pigment into the scalp to replicate the appearance of natural hair follicles.
Key Benefits:
Instant Camouflage: Effectively masks scalp visibility, creating the illusion of a closely shaved head or greater density.
No Downtime:
Results. A quick procedure with immediate visual
Versatile:
Excellent as a standalone solution or to enhance the results of other treatments.
Ideal for:
Advanced baldness (Norwood Scale III-VI), receding hairlines, and areas where follicles are no longer present.
The Science:
When follicles are permanently lost, we must redistribute them. We use the Follicular Unit Extraction (FUE) method to meticulously harvest genetically resistant hair follicles from the back of your scalp and implant them into the thinning areas.
Key Benefits:
Permanent, Natural Results: The transplanted hair is your own and will grow naturally for a lifetime.
Restores Hairlines and Density:
youthful frame for your face. Recreates a natural, Optimal Long-Term Solution: For significant loss, this is the gold standard. We often recommend combining a transplant with VEGF-A therapy to ensure the newly implanted grafts thrive and to protect the surrounding native hair.
Ideal for:
Moderate thinning, areas with poor circulation, and as a powerful adjunct to hair transplants.
The Science:
This is a groundbreaking treatment that addresses the vascular cause of hair loss. We use a non-integrating gene therapy vector to deliver the VEGF-A gene directly to your scalp cells. This gene instructs your body to produce new blood vessels (angiogenesis).
Key Benefits:
Ideal for:
Early-stage thinning, diffuse hair loss, and enhancing overall hair health.
The Science:
Our Pluripotent Exosomes (PXHair) are powerful signaling molecules harvested from embryonic stem cells. When applied after microneedling, they deliver a concentrated set of instructions to your dormant follicles.
Key Benefits:
Re-educates Follicles: Signals miniaturized follicles to re-enter the active growth (anagen) phase.
Empty fat cells, don’t destroy them. Our non-invasive red light therapy targets the mitochondria within your fat cells, enhancing their function and encouraging the release of stored lipids. This “fat-emptying” approach shrinks fat cells naturally, supports mitochondrial energy production, and contours the body without surgery, downtime, or the destruction of tissue.
Experience the future of weight management. While GLP-1 agonists manage appetite, our pioneering FGF21 minicircle gene therapy reengineers your metabolism itself. A single annual injection instructs your body to:
Follistatin plays a significant role in metabolic health by enhancing insulin sensitivity and promoting glucose uptake in muscle and adipose tissue, helping to maintain stable blood sugar levels and offering a promising approach for managing type 2 diabetes and metabolic syndrome. It also supports fat reduction by increasing muscle mass, which elevates basal metabolic rate, while encouraging the browning of white adipose tissue to boost energy expenditure and reduce fat storage. Additionally, follistatin provides hepatic protection by helping prevent fatty liver disease and fibrosis through the inhibition of pro-fibrotic TGF-β signaling.
The journey to metabolic health begins in the gut. We use targeted peptides and advanced Traditional Chinese Medicine (TCM) formulations to restore gut integrity, reduce inflammation, and optimize the critical communication between your digestive system and brain. This foundational work improves nutrient absorption, reduces cravings, and creates a balanced internal environment for lasting change.
Experience deep, targeted brainwave states with immersive sound, precise vibration, as well as specific light wavelengths to modulate brain activity. These non-invasive technology promote relaxation, reduce mental fatigue, and enhance overall cognitive clarity.
Peak brain function requires a balanced nervous system. We provide you with advanced wearables and AI-guided biofeedback protocols to optimize your Heart Rate Variability (HRV). By training your body’s stress response, you gain mastery over your mental state, improving focus, emotional regulation, and recovery.
The brain depends on a dense microvascular network to function optimally.
VEGF-A (Vascular Endothelial Growth Factor A) promotes:
Because VEGF-A acts locally, it has to be used in a targeted manner to stimulate vascular regeneration.
This rebuilds the biological infrastructure that supports brain performance.
Go beyond symptom management. We utilize specific peptides and the groundbreaking CN105 peptide, designed to provide powerful neuroprotective and cognitive-enhancing effects. This approach helps shield neurons from damage, reduce inflammation, and stimulate the repair of neural pathways, laying the foundation for a stronger, more resilient brain.
Cognitive decline is often driven by reduced cellular energy rather than neuron loss.
FGF21 (Fibroblast Growth Factor 21) plays a critical role in:
FGF21 ensures that neurons maintain the energy required to function, adapt, and recover.
At the core of the protocol is Klotho, a protein strongly associated with extended lifespan and cognitive performance.
Klotho supports:
By restoring Klotho levels, we help preserve neural network integrity, a key determinant of brainspan.
At Blast Longevity, we believe your brain’s potential is not fixed. It is a dynamic, adaptable system waiting to be optimized. Our Brain Enhancement Program is a comprehensive, science-powered protocol designed to not only restore age-related decline but to propel your cognitive function far beyond conventional limits. Achieve unparalleled mental clarity, fortify your neural resilience, and unlock a state of sustained peak performance.